ALDX | Aldeyra Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.92 - 6.30
52 Week Range	1.4200 - 7.42
Beta	0.89
Implied Volatility	99.66%
IV Rank	27.37%
Day's Volume	507,836
Average Volume	489,672
Shares Outstanding	59,421,600
Market Cap	364,254,408
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-05-02

Valuation
Profitability
Growth
Health
P/E Ratio	-9.58
Forward P/E Ratio	N/A
EPS	-0.64
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	10
Country	USA
Website	ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

ALDX's peers: TARS, LIAN, TVTX, ETON, VRDN, TERN, GPCR, BPMC, ETNB, XFOR, INZY, DAWN, HOOK, PHAT, LYRA, CGEM, BLRX, ARDX, LXRX, MCRB, IBRX, BCLI, CANF, CRMD, ENLV, EVGN, ORMP, PLX, VERA

*Chart delayed

Analyzing fundamentals for ALDX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ALDX Fundamentals page.

Watching at ALDX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ALDX Technicals page.